Back
Science

Oral Antiviral Candidate Blocks Measles-Like Virus Transmission in Ferret Study

Generated on: Last updated: 2 sources
View source

"The drug candidate is reported to be the first oral viral polymerase inhibitor shown to completely prevent airborne transmission in this animal model."

Breakthrough in Antiviral Research: Oral Drug Candidate GHP-88310 Blocks Measles-Like Virus Transmission

A new study published in Nature Microbiology reveals that the oral antiviral drug candidate GHP-88310 successfully prevented the transmission of canine distemper virus (CDV)—a virus that causes measles-like disease—in ferrets when administered both before and after exposure.

The research was conducted by the Center for Translational Antiviral Research (CTAR) at Georgia State University.

Study Methodology

Researchers developed a system to pair infected and uninfected ferrets in either direct contact or shared airspace under controlled conditions.

This model was designed to simulate human transmission scenarios, including spread within households and indoor settings such as classrooms.

Key Findings

  • GHP-88310, a broad-spectrum inhibitor of viral polymerase, was tested in ferrets infected with CDV.
  • Prophylactic administration (shortly before or after exposure) prevented virus transmission through both direct contact and airborne exposure.
  • Therapeutic administration reduced the duration of infectiousness and the severity of symptoms in infected animals.
  • The drug candidate is reported to be the first oral viral polymerase inhibitor shown to completely prevent airborne transmission in this animal model.

Public Health Context

Measles has reemerged in North America since 2025. In the United States, this has resulted in thousands of infections, hundreds of hospitalizations, and three deaths across multiple states. Concurrent outbreaks in Canada and Mexico have challenged the region's measles elimination status.

Future Development

Investigators are preparing GHP-88310 for formal clinical testing. Researchers have noted the drug could serve as a supplement to traditional ring vaccination strategies.

The study was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.